IP Verse

Antitumor Agent And Antitumor Effect Enhancer - EP3042669

The patent EP3042669 was granted to Taiho Pharmaceutical on Mar 8, 2023. The application was originally filed on Sep 5, 2014 under application number EP14842538A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3042669

TAIHO PHARMACEUTICAL
Application Number
EP14842538A
Filing Date
Sep 5, 2014
Status
Granted And Under Opposition
Feb 3, 2023
Publication Date
Mar 8, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKDec 7, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE
CAMULONNov 29, 2023REDDIE & GROSEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO9630346
INTERNATIONAL-SEARCH-REPORTWO2014157443
INTERNATIONAL-SEARCH-REPORTWO2014157444
OPPOSITIONEP1849470
OPPOSITIONWO2015034032

Non-Patent Literature (NPL) Citations (39) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BR J CANCER, (2007), vol. 96, no. 2, pages 231 - 40
DESCRIPTION- CLIN CANCER RES., (2000), vol. 6, no. 2, pages 701 - 8
DESCRIPTION- CLINICAL CANCER RESEARCH, (1998), vol. 4, pages 2957 - 2966
DESCRIPTION- CURR CANCER DRUG TARGETS, (2010), vol. 10, no. 1, pages 80 - 95
DESCRIPTION- CURR ONCOL REP, (2012), vol. 14, no. 4, pages 277 - 84
DESCRIPTION- EUR J CANCER, (2007), vol. 43, no. 1, pages 175 - 83
DESCRIPTION- INVEST NEW DRUGS., (2008), vol. 26, no. 1, pages 1 - 5
DESCRIPTION- INVEST NEW DRUGS, (2008), vol. 26, no. 5, pages 445 - 54
DESCRIPTION- J RADIAT RES., (2007), vol. 48, no. 3, pages 187 - 95
DESCRIPTION- J RADIAT RES., (2011), vol. 52, no. 5, pages 646 - 54
DESCRIPTION- LANCET ONCOL., (2012), vol. 13, no. 10, pages 993 - 1001
DESCRIPTION- PATHOL ONCOL RES., (2010), vol. 16, no. 2, pages 143 - 8
INTERNATIONAL-SEARCH-REPORT- TEMMINK, OH. ET AL., "Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine", EUR. J. CANCER, (2007), vol. 43, no. 1, pages 175 - 183, XP005834920
INTERNATIONAL-SEARCH-REPORT- KUBOKI, Y. ET AL., "A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With chemotherapy-refractory Metastatic Colorectal Cancer (mCRC", EUROPEAN JOURNAL OF CANCER, (2011), vol. 47, no. SUPPL., page S392, XP055146518
INTERNATIONAL-SEARCH-REPORT- YOSHINO, T. ET AL., "TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial", LANCET ONCOL., (2012), vol. 13, no. 10, pages 993 - 1001, XP002762779
INTERNATIONAL-SEARCH-REPORT- TEMMINK, OH. ET AL., "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies", CANCER SCI., (2007), vol. 98, no. 6, pages 779 - 789, XP055281121
INTERNATIONAL-SEARCH-REPORT- BIJNSDORP, IV. ET AL., "Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines", CANCER SCI., (2010), vol. 101, no. 2, pages 440 - 447, XP055322963
OPPOSITION- Anonymous, "Avastin FDA Label", accessdata.fda.gov accessdata.fda, (20110101), pages 1 - 25, accessdata.fda.gov accessdata.fda , URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125085s225lbl.pdf, (20231130), XP093107439
OPPOSITION- Anonymous, "AVASTIN HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, (20090501), pages 1 - 22, FDA, (20190919), XP055624017
OPPOSITION- Anonymous, "ERBITUX ® (cetuximab) injection ", accessdata.fda.gov, (20090101), pages 1 - 21, accessdata.fda.gov, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125084s273lbl.pdf, (20231130), XP093107441
OPPOSITION- Anonymous, "ERBITUX- HIGHLIGHTS OF PRESCRIBING INFORMATION ", (20120101), (20240405), XP093148397
OPPOSITION- Anonymous, "ERBITUX - HIGHLIGHTS OF PRESCRIBING INFORMATION ", (20210401), URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s277s280lbl.pdf, (20240405), XP093148393
OPPOSITION- Anonymous, "VECTIBIX - HIGHLIGHTS OF PRESCRIBING INFORMATION ", (20090701), URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf, (20240405), XP093148401
OPPOSITION- Anonymous, "VECTIBIX - HIGHLIGHTS OF PRESCRIBING INFORMATION ", (20210801), (20240405), XP093148406
OPPOSITION- Anonymous, "Vectibix® (panitumumab) Solution for Intravenous Infusion", accessdata.fda.gov/, (20090101), pages 1 - 14, accessdata.fda.gov/, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdf, (20231130), XP093107443
OPPOSITION- Evans Scott R, "Fundamentals of clinical trial design", J Exp Stroke Transl Med. 2010 January 1; 3(1): 19-27., (20100101), pages 1 - 12, J Exp Stroke Transl Med. 2010 January 1; 3(1): 19-27., URL: https://pubmed.ncbi.nlm.nih.gov/21533012/, (20221027), XP055975391
OPPOSITION- Herbert HURWITZ et al., "Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cance", The New England Journal of Medicine, (2004), vol. 350, page 23, XP002302382
OPPOSITION- Temmink Olaf H., "Role of thymidine phosphorylase/platelet-derived endothelial cell growth factor inhibition in the cytotoxicity of fluoropyrimidines", Doctoral Thesis, Vrije Universiteit Amsterdam, (20070101), Doctoral Thesis, Vrije Universiteit Amsterdam, URL: https://research.vu.nl/ws/portalfiles/portal/42201136/complete+dissertation.pdf, (20240405), XP093148384
OPPOSITION- Temmink, O.H. Hoebe, E.K. Fukushima, M. Peters, G.J., "Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20070110), vol. 43, no. 1, doi:10.1016/j.ejca.2006.08.022, ISSN 0959-8049, pages 175 - 183, XP005834920
OPPOSITION- Y. Kuboki, T. Yoshino, K. Yamazaki, T. Nishina, Y. Komatsu,, "A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC)", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20110901), vol. 47, no. Suppl. 1, doi:10.1016/S0959-8049(11)71650-1, ISSN 0959-8049, page S392, XP055146518
OPPOSITION- Dr Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, Tomohiro Nishina, Yoshito Komatsu, Prof Hideo Baba, Akihito Tsuji, Kensei Yamaguchi, Kensei Yamaguchi, Kei Muro, Naotoshi Sugimoto, Yasushi Tsuji, Toshikazu Moriwaki, Taito Esaki, Prof Chikuma Hamada, Takanori Tanase, Atsushi Ohtsu, "TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20121001), vol. 13, no. 10, doi:10.1016/S1470-2045(12)70345-5, pages 993 - 1001, XP002762779
OPPOSITION- Takayuki YOSHINO et al., "TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double- blind, randomised, placebo-controlled phase 2 trial", Lancet Oncol, (2012), vol. 13, doi:10.1016/S1470-2045(12)70345-5, XP002762779
OPPOSITION- O H Temmink, Hoebe E K, Van Der Born K, Ackland S P, Fukushima M, Peters G J, "Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells", British Journal of Cancer, Nature Publishing Group UK, London, London, (20070129), vol. 96, no. 2, doi:10.1038/sj.bjc.6603549, ISSN 0007-0920, pages 231 - 240, XP055229001
OPPOSITION- Goodwin Rachel, Asmis Timothy, "Overview of Systemic Therapy for Colorectal Cancer", Clinics in Colon & Rectal Surgery, Thieme Medical Publishers, US, US , (20091101), vol. 22, no. 04, doi:10.1055/s-0029-1242465, ISSN 1531-0043, pages 251 - 256, XP093107436
OPPOSITION- Olaf H. Temmink, Tomohiro Emura, Michiel De Bruin, Masakazu Fukushima, Godefridus J. Peters, "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20070601), vol. 98, no. 6, doi:10.1111/j.1349-7006.2007.00477.x, ISSN 1347-9032, pages 779 - 789, XP055281121
OPPOSITION- Irene V. Bijnsdorp, Frank A. E. Kruyt, Masakazu Fukushima, Kees Smid, Shanti Gokoel, Godefridus J. Peters, "Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20100201), vol. 101, no. 2, doi:10.1111/j.1349-7006.2009.01375.x, ISSN 1347-9032, pages 440 - 447, XP055322963
OPPOSITION- Chibaudel Benoist, Tournigand Christophe, André Thierry, De Gramont Aimery, "Therapeutic strategy in unresectable metastatic colorectal cancer", Therapeutic Advances in Medical Oncology, SAGE Publishing, (20120301), vol. 4, no. 2, doi:10.1177/1758834011431592, ISSN 1758-8359, pages 75 - 89, XP093107434
OPPOSITION- Clarke Robert, "The role of preclinical animal models in breast cancer drug development", Breast Cancer Research, (20091218), vol. 11(Suppl 3), no. S22, doi:10.1186/bcr2441, ISSN 1465-542X, pages 1 - 3, XP093192603
SEARCH- O H TEMMINK ET AL, "Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells", BRITISH JOURNAL OF CANCER, GB, (20070129), vol. 96, no. 2, doi:10.1038/sj.bjc.6603549, ISSN 0007-0920, pages 231 - 240, XP055229001 [X] 1-10 * final paragraph of the discussion *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents